-+ 0.00%
-+ 0.00%
-+ 0.00%
Yuandong Biology (688513.SH): Phase II/III clinical trial of EP-0226 tablets for post-herpes zoster neuralgia completed the first patient administration
Share
Listen to the news

Zhitong Finance App News, Yuandong Biology (688513.SH) announced that the first-class chemical innovation drug EP-0226 tablets jointly developed by the company, the Shanghai Institute of Pharmaceutical Sciences of the Chinese Academy of Sciences and the Zhongke Zhongshan Pharmaceutical Innovation Research Institute are undergoing a multi-center, randomized, double-blind, double-blind, double-simulation, placebo and pregabalin capsules in patients with post-herpes zoster neuralgia in China. Recently, the first case of patient administration was completed.

EP-0226 tablets are a novel calcium ion channel modulator. It has a high affinity with the α2delta subunit in central nervous system tissues. Its mechanism of action is to reduce the internal flow of calcium ions into neurons by binding to the α2delta subunit of the calcium ion channel, thereby reducing the release of excitatory neurotransmitters such as glutamate and norepinephrine, thereby effectively controlling neuropathic pain.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending